Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT6A | Q92794 | 2/20 | 0.33 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11028444 | 0.87 | CES2 (0.41) | KAT6ACTSSP2RX1HPGD | |
| SCHEMBL11028441 | 0.87 | CES2 (0.41) | KAT6ACTSSP2RX1HPGD | |
| SCHEMBL11938690 | 0.83 | — | — | |
| SCHEMBL989877 | 0.82 | PTPN1 (0.41) | KMT2AMEN1GAA | |
| SCHEMBL6917559 | 0.82 | PTPN1 (0.41) | KMT2AMEN1GAA | |
| SCHEMBL15835720 | 0.81 | KMT2A (0.35) | KAT6ACTSSKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL15835718 | 0.81 | KAT6A (0.34) | KAT6AKMT2AGAAHPGD | |
| SCHEMBL20271951 | 0.72 | DGAT1 (0.33) | KMT2AMEN1SMN1; SMN2GAAHPGD | |
| SCHEMBL14599856 | 0.72 | KAT6A (0.40) | KAT6AKMT2AMEN1SMN1; SMN2HPGD | |
| SCHEMBL11023932 | 0.70 | CES2 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8940734-B2 | Fused aminodihydrothiazine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-01-27 | — | — | US | disclosed |
| US-20140142091-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-05-22 | — | — | US | disclosed |
| US-20130203740-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-08-08 | — | — | US | disclosed |
| US-8338407-B2 | Fused aminodihydrothiazine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-12-25 | — | — | US | disclosed |
| US-20120190672-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190672-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | BACE1, APP, BACE2 | KAT6A 2042/4885MRGPRX4 2808/4885CTSS 930/4885 |
| US-20140142091-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | BACE1, APP, BACE2 | KAT6A 2042/4885MRGPRX4 2808/4885CTSS 930/4885 |
| US-20130203740-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | BACE1, APP, BACE2 | KAT6A 2042/4885MRGPRX4 2808/4885CTSS 930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.